Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

466

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: INCB123667
DRUG: Investigator's choice of chemotherapy

Sponsor

Incyte Corporation

Collaborators

[object Object]
[object Object]